APA (7th ed.) Citation

Abdollahi, A., Favata, M., Weber, M., Roman, V., Hess, R., Hammond, K., . . . Amador-Arjona, A. (2025). The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer. PLoS ONE, 20(8), 1. https://doi.org/10.1371/journal.pone.0327588

Chicago Style (17th ed.) Citation

Abdollahi, Angela, et al. "The FGFR Inhibitor Pemigatinib Overcomes Cancer Drug Resistance to KRAS G12C Inhibitors in Mesenchymal Lung Cancer." PLoS ONE 20, no. 8 (2025): 1. https://doi.org/10.1371/journal.pone.0327588.

MLA (9th ed.) Citation

Abdollahi, Angela, et al. "The FGFR Inhibitor Pemigatinib Overcomes Cancer Drug Resistance to KRAS G12C Inhibitors in Mesenchymal Lung Cancer." PLoS ONE, vol. 20, no. 8, 2025, p. 1, https://doi.org/10.1371/journal.pone.0327588.